维普期刊资源整合服务平台（V6.5）

89篇 您的检索式：作者名="Arkenau"

选中清除导出查看参考文献查看引证文献引用追踪共5页首页上一页第1页下一页末页 /5 跳转

	题名	作者	年代	出处	被引量
1	Advanced gastric cancer:Is there enough evidence to call second-line therapy standard?显示文摘Gastric cancer and cancer of the gastro-oesophageal junction(GOJ) are the 4th most common cancer diagnoses worldwide with regional differences in incidence rates.The treatment of gastric and GOJ cancers is complex and requires multimodality treatment including chemotherapy treatment,surgery,and radiotherapy.During the past decade considerable improvements were achieved by advanced surgical techniques,tailored chemotherapies/radiotherapy and technical innovations in clinical diagnostics.In patients with advanced or metastatic gastric/GOJ cancer systemic chemotherapy with fluoropyrimidine/platinum-based regimens(+/-human epidermal growth factor receptor-2 antibody) is the mainstay of treatment.Despite these improvements,the clinical outcome for patients with advanced or metastatic disease is generally poor with 5-year survival rates ranging between 5%-15%.These poor survival rates may to some extent be related that standard therapies beyond first-line therapies have never been defined.Considering that this patient population is often not fit enough to receive further treatments there is an increasing body of evidence from phase-2 studies that in fact second-line therapies may have a positive impact in terms of overall survival.Moreover two recently published phase-3 studies support the use of second-line chemotherapy.A South Korean study compared either,irinotecan or docetaxel with best supportive care and a German study compared irinotecan with best supportive care-both studies met their primary endpoint overall survival.In this 'Field of Vision' article,we review these recently published phase-3 studies and put them into the context of clinical prognostic factors helping to guide treatment decisions in patients who most likely benefit.	Hendrik-Tobias Arkenau Matilde Saggese Charlotte Lemech	2012	World Journal of Gastroenterology2012，18，44：	12
2	Circulating tumour cell (CTC) counts as intermediate end points in castratmn-remstant prostate cancer ( CRPC ) : a single- centre experience显示文摘	Olmos D Arkenau HT Ang JE	2009	Ann Oncol2009，20，1：	1
3	A phase Ⅰ dose escalation study of AT9283,a small molecule inhibitor of aurora kinases in patients with advanced solid malignancies显示文摘	ARKENAU H T PLUMMER R MOLIFE L R	2012	Ann Oncol2012，23，5：	1
4	Phase M study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer:a final report of the AIO Colorectal Study Group显示文摘	PORSCHEN R ARKENAU H T KUBICKA S	2007	J Clin Oncol2007，25，27：	1
5	Gemeitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience显示文摘	Arkenau HT Chong G Cunningham D	2007	Haematologica2007，92，2：	1
6	Phase Ⅲ study of eapeeitabine plus oxaliplatin compared with fluorouraeil and leueovorin plus oxaliplatin in metastatic eoloreetal cancer: a final report of the AIO Cotoreeud Study Group显示文摘	Porsehen R Arkenau HT Kubicka S	2007	J Clin Oncol2007，25，27：	1
7	Gemeitabine, eisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience 显示文摘	Arkenau H T Chong G Cunningham D	2007	Haematologica2007，92，2：	1
8	Phase Ⅲ study of capecitabine plus oxaliplatin compared with fluorouracil and leu covorin plus oxaliplatin in metastatic colorectal cancer: A final report of the AIO colorectal study group显示文摘	Porschen R Arkenau H T Kubicka S	2007	J Clin Oncol2007，25，27：	1
9	Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/ leucovorin in patients with metastatic colorectal cancer:a pooled analysis of randomized trials显示文摘	ARKENAU H T ARNOLD D CASSIDY J	2008	J Clin Oncol2008，26，36：	1
10	Oxaliplatin fiuorouracil and leucovorin for advanced biliary tract system adenocarcinomas: a prospective phase II trial显示文摘	Nehls 0 Klump B Arkenau HT	2002	Br J Cancer2002，87，7：	1
11	Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience显示文摘	Olmos D Arkenau HT AngJE	2009	Ann Oncol2009，20，1：	1
12	Clinical impact of checkpoint inhibitors as novel cancer therapies 显示文摘	Shih K Arkenau HT Infante JR	2014	Drugs2014，74，17：	1
13	Phase IlI study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer:a final report of the AIO Colorectal Study Group 显示文摘	Porschen R Arkenau HT Kubicka S	2007	J Clin Oncol2007，25，27：	1
14	Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in pa- tients with metastatic colorectal cancer: a pooled analysis of randomized trials 显示文摘	Arkenau HT Arnold D Cassidy J	2008	J Clin 0ncol2008，26，36：	1
15	Clinical impact of checkpoint inhibitors as novel cancer therapies 显示文摘	Sbih K Arkenau HT Infante JR	2014	Drugs2014，74，17：	1
16	Daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: updated results of a phase 1/2 study ( GEN503 ) 显示文摘	Plesner T Arkenau HT Gimsing P	2015	Blood2015，126，23：	1
17	Oxaliplatin in combination with 5-fluorouracil/leucovorin or capecitabine in elderly patients with metastatic colorectal cancer 显示文摘	Arkenau HT Graeven U Kubieka S	2008	Clin Colorectal Cancer2008，7，1：	1
18	Phase Ⅲ study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group 显示文摘	Porschen R Arkenau HT Kubicka S	2007	J Clin Oncol2007，25，27：	1
19	Phase I clinical and pharmacologic study of the focal adhesion kinase (FAK) inhibitor GSK2256098 in pts with advanced solid tumors显示文摘	Soria J-C Gan H K Arkenau H- T	2012	J Clin Oneol2012，30，15：	1
20	Circulating tumour cell(CTC)counts an intermediate end points in castration resistant prostate cancer(CRPC):a single centre experience显示文摘	Olmos D Arkenau HT Ang JE	2009	Ann Oncol2009，20，1：	1

返回顶部每页显示：

共5页首页上一页第1页下一页末页 /5 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示